News | September 08, 2010

IVUS-Guided Bifurcation Stenting Helps Improve Outcomes


September 8. 2010 – Intravascular ultrasound (IVUS)-guided bifurcation stenting significantly reduced the four-year mortality in patients as compared to conventional angiographically guided stenting, according to a recent study.

The study, supported in part by the Cardiovascular Research Foundation, was conducted in Seoul, South Korea and published in the Sept. 1 issue of the American Journal of Cardiology (volume 106, issue 5 , pages 612-618, Sept. 1, 2010).

In addition, researchers found IVUS guidance reduced the development of very late stent thrombosis in patients receiving drug-eluting stents (DES).

Stenting for bifurcation lesions is challenging and the effect of IVUS guidance on long-term outcomes has not been evaluated. Researchers assessed the long-term outcomes of IVUS-guided stenting in bifurcation lesions in 758 patients with de novo nonleft main coronary bifurcation lesions. They compared adverse outcomes (i.e., death, stent thrombosis, and target lesion revascularization) within four years, after adjustment using a multivariate Cox proportional hazard model and propensity scoring.

IVUS-guided stenting significantly reduced the long-term all-cause mortality in the total population and in the patients receiving DESs, but not in the patients receiving bare metal stents. IVUS-guided stenting had no effect on the rate of stent thrombosis or target lesion revascularization. In patients receiving DESs, however, IVUS guidance reduced the development of very late stent thrombosis (0.4 vs. 2.8 percent).

For more information: www.ajconline.org


Related Content

News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2025 — A major international study published in Atherosclerosis* has found that routinely testing for ...

Home August 20, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 4, 2025 — Marea Therapeutics, Inc., a clinical-stage biotechnology company that develops next-generation medicines ...

Home August 04, 2025
Home
News | Cardiovascular Clinical Studies

July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic ...

Home July 22, 2025
Home
News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
Subscribe Now